CA2521812A1 - Vaccin polyvalent optimal contre le cancer - Google Patents
Vaccin polyvalent optimal contre le cancer Download PDFInfo
- Publication number
- CA2521812A1 CA2521812A1 CA002521812A CA2521812A CA2521812A1 CA 2521812 A1 CA2521812 A1 CA 2521812A1 CA 002521812 A CA002521812 A CA 002521812A CA 2521812 A CA2521812 A CA 2521812A CA 2521812 A1 CA2521812 A1 CA 2521812A1
- Authority
- CA
- Canada
- Prior art keywords
- antigens
- cancer
- vaccine
- cell
- polyvalent vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 44
- 201000011510 cancer Diseases 0.000 title claims abstract description 38
- 229940031348 multivalent vaccine Drugs 0.000 title claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 75
- 108091007433 antigens Proteins 0.000 claims abstract description 75
- 239000000427 antigen Substances 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000005847 immunogenicity Effects 0.000 claims abstract description 11
- 238000001514 detection method Methods 0.000 claims abstract description 9
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 52
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 50
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 41
- 239000002253 acid Substances 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 19
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 claims description 12
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000002784 cytotoxicity assay Methods 0.000 claims description 2
- 231100000263 cytotoxicity test Toxicity 0.000 claims description 2
- XBSNXOHQOTUENA-KRAHZTDDSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO XBSNXOHQOTUENA-KRAHZTDDSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 102
- 230000000295 complement effect Effects 0.000 description 20
- 230000009257 reactivity Effects 0.000 description 18
- 230000001404 mediated effect Effects 0.000 description 16
- 102100022002 CD59 glycoprotein Human genes 0.000 description 15
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 15
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 15
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 13
- 238000001574 biopsy Methods 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000024203 complement activation Effects 0.000 description 8
- 229930186217 Glycolipid Natural products 0.000 description 7
- 239000000568 immunological adjuvant Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 125000005630 sialyl group Chemical group 0.000 description 6
- 108010060123 Conjugate Vaccines Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 108010063954 Mucins Proteins 0.000 description 5
- 102000015728 Mucins Human genes 0.000 description 5
- 229940031670 conjugate vaccine Drugs 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 4
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940051875 mucins Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108010009575 CD55 Antigens Proteins 0.000 description 2
- 108010055167 CD59 Antigens Proteins 0.000 description 2
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 2
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229940125507 complex inhibitor Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical group 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- KGUMAAYFQYKEJT-QMLHLINFSA-N (2S,4S,5R,6R)-5-acetamido-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]4O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC KGUMAAYFQYKEJT-QMLHLINFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- -1 GD3 ganglioside Chemical class 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 102100025067 Potassium voltage-gated channel subfamily H member 4 Human genes 0.000 description 1
- 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000210647 Salmonella enterica subsp. enterica serovar Montevideo Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- LGRBZCLULGFXOD-DQMMGUQESA-L disodium (2S,4S,5R,6R)-5-acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxylato-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxyoxane-2-carboxylate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O3)[C@H](O)[C@H](O)CO)C([O-])=O)C([O-])=O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC LGRBZCLULGFXOD-DQMMGUQESA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 201000004169 miliaria rubra Diseases 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940031351 tetravalent vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46162203P | 2003-04-09 | 2003-04-09 | |
| US60/461,622 | 2003-04-09 | ||
| PCT/US2004/011122 WO2004091507A2 (fr) | 2003-04-09 | 2004-04-09 | Vaccin polyvalent optimal contre le cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2521812A1 true CA2521812A1 (fr) | 2004-10-28 |
Family
ID=33299843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002521812A Abandoned CA2521812A1 (fr) | 2003-04-09 | 2004-04-09 | Vaccin polyvalent optimal contre le cancer |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1615614A4 (fr) |
| JP (1) | JP2006522828A (fr) |
| CA (1) | CA2521812A1 (fr) |
| WO (1) | WO2004091507A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1458242A4 (fr) | 2001-07-06 | 2006-06-07 | Sloan Kettering Inst Cancer | Vaccin conjugue polyvalent contre le cancer |
| US20060035267A1 (en) * | 2003-04-09 | 2006-02-16 | Livingston Philip O | Optimal polyvalent vaccine for cancer |
| PL1960434T3 (pl) | 2005-12-08 | 2012-12-31 | Squibb & Sons Llc | Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1 |
| US9125848B2 (en) | 2010-06-10 | 2015-09-08 | The Cleveland Clinic Foundation | Alpha lactalbumin immunization methods |
| WO2013158553A1 (fr) | 2012-04-16 | 2013-10-24 | The Cleveland Clinic Foundation | Vaccin multivalent contre le cancer du sein |
| JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
| WO2017216098A1 (fr) * | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | Dosage et procédé de détermination d'anticorps induisant la cdc |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1458242A4 (fr) * | 2001-07-06 | 2006-06-07 | Sloan Kettering Inst Cancer | Vaccin conjugue polyvalent contre le cancer |
-
2004
- 2004-04-09 CA CA002521812A patent/CA2521812A1/fr not_active Abandoned
- 2004-04-09 EP EP04759415A patent/EP1615614A4/fr not_active Ceased
- 2004-04-09 JP JP2006509902A patent/JP2006522828A/ja active Pending
- 2004-04-09 WO PCT/US2004/011122 patent/WO2004091507A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004091507A2 (fr) | 2004-10-28 |
| WO2004091507A3 (fr) | 2005-12-15 |
| JP2006522828A (ja) | 2006-10-05 |
| EP1615614A4 (fr) | 2007-08-22 |
| EP1615614A2 (fr) | 2006-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060035267A1 (en) | Optimal polyvalent vaccine for cancer | |
| Ragupathi et al. | Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity | |
| Livingston et al. | Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy | |
| US10792349B2 (en) | Galectin-3 as immunological target | |
| Dickler et al. | Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer | |
| Zappasodi et al. | Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death | |
| Krug et al. | Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin | |
| Sabbatini et al. | Immunization of ovarian cancer patients with a synthetic Lewisy‐protein conjugate vaccine: A phase 1 trial | |
| Ragupathi et al. | A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle | |
| Reed et al. | Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival | |
| Vural et al. | Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters | |
| Gregor et al. | Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination | |
| JP5876411B2 (ja) | ポルフィロモナス・ジンジバリス（Ｐｏｒｐｈｙｒｏｍｏｎａｓｇｉｎｇｉｖａｌｉｓ）ポリペプチド | |
| Dettling et al. | Identification of CRKII, CFL1, CNTN1, NME2, and TKT as novel and frequent T-cell targets in human IDH-mutant glioma | |
| Trabbic et al. | Immunological evaluation of the entirely carbohydrate-based Thomsen-Friedenreich–PS B conjugate | |
| CA2521812A1 (fr) | Vaccin polyvalent optimal contre le cancer | |
| US20120064102A1 (en) | Peptide inducing xage-1b-specific immune reaction and utilization of same | |
| Zhang et al. | Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides | |
| Zhao et al. | Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases | |
| Manjili et al. | Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals” | |
| US20070116704A1 (en) | Method for the production of an immunostimulating mucin (muc1) | |
| US20080241195A1 (en) | Optimal Polyvalent Vaccine for Cancer | |
| Ritter et al. | Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni | |
| Cappello et al. | Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells | |
| CA2643737C (fr) | Vaccin contre le cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |